Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Adeptus Biotechnologies Corp. (ADPT) PT Raised to $11 at Morgan Stanley
August 6, 2025 7:56 AM EDTMorgan Stanley analyst Tejas Savant raised the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $11.00 (from $9.00) while maintaining a Equalweight rating.
The analyst comments "Another solid beat/raise as clonoSEQ volume/ASP momentum continues on payor traction, community/EMR uptake; MRD EBITDA... More
